NRx Pharmaceuticals (NASDAQ:NRXP) Price Target Raised to $45.00

NRx Pharmaceuticals (NASDAQ:NRXP) had its price target increased by HC Wainwright from $40.00 to $45.00 in a research report released on Tuesday, Marketbeat reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for NRx Pharmaceuticals’ Q3 2026 earnings at $0.03 EPS, Q4 2026 earnings at $0.06 EPS, FY2026 earnings at $0.13 EPS, FY2027 earnings at $1.23 EPS, FY2028 earnings at $3.18 EPS, FY2029 earnings at $5.06 EPS and FY2030 earnings at $6.15 EPS.

NRXP has been the topic of a number of other reports. Zacks Research lowered NRx Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Monday, January 26th. Wall Street Zen upgraded shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, November 23rd. Ascendiant Capital Markets reiterated a “buy” rating and set a $48.00 price objective (up from $47.00) on shares of NRx Pharmaceuticals in a research report on Friday, January 2nd. D. Boral Capital reissued a “buy” rating and set a $34.00 target price on shares of NRx Pharmaceuticals in a research note on Tuesday, February 17th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $38.00.

NRx Pharmaceuticals Trading Down 5.3%

Shares of NRXP opened at $1.77 on Tuesday. The stock’s 50-day moving average price is $2.10 and its two-hundred day moving average price is $2.50. NRx Pharmaceuticals has a 12 month low of $1.58 and a 12 month high of $3.84. The company has a market capitalization of $56.41 million, a PE ratio of -0.75 and a beta of 1.97.

Institutional Investors Weigh In On NRx Pharmaceuticals

Large investors have recently bought and sold shares of the stock. Geode Capital Management LLC increased its stake in NRx Pharmaceuticals by 27.9% in the second quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock valued at $562,000 after purchasing an additional 37,598 shares in the last quarter. Ethos Financial Group LLC acquired a new stake in shares of NRx Pharmaceuticals in the 3rd quarter valued at about $39,000. One Wealth Management Investment & Advisory Services LLC increased its position in NRx Pharmaceuticals by 86.1% in the 3rd quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock valued at $92,000 after buying an additional 12,950 shares in the last quarter. AdvisorShares Investments LLC raised its stake in NRx Pharmaceuticals by 29.7% during the 3rd quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock worth $1,129,000 after buying an additional 78,339 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in NRx Pharmaceuticals by 18.3% in the third quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock worth $1,765,000 after acquiring an additional 82,781 shares in the last quarter. 4.27% of the stock is currently owned by institutional investors and hedge funds.

NRx Pharmaceuticals News Summary

Here are the key news stories impacting NRx Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright sharply raised multi-year EPS forecasts and reiterated a Buy rating with a $45 price target, projecting material earnings growth from FY2026 through FY2029 (Q4‑2026: $0.06; FY2026: $0.13; FY2027: $1.23; FY2028: $3.18; FY2029: $5.06). This signals that at least one boutique analyst expects a strong recovery and significant upside vs. the current share price. HC Wainwright Forecasts Strong Price Appreciation for NRx Pharmaceuticals (NASDAQ:NRXP) Stock
• Neutral Sentiment: Zacks Research moved NRXP from “strong sell” to “hold,” reducing one source of bearish pressure but not endorsing a buy — a modest signal that downside may be stabilizing but not yet reversed. Zacks upgrade coverage (TickerReport)
• Negative Sentiment: HC Wainwright trimmed its Q3‑2026 EPS estimate (from $0.04 to $0.03), a near-term downgrade that tempers some of the upbeat multi-year outlook and highlights potential short-term execution or timing risk. MarketBeat NRXP coverage (analyst notes)
• Negative Sentiment: Consensus still shows a current full-year loss (consensus ~($1.75) EPS), so HC Wainwright’s optimistic projections are aggressive and depend on successful product/commercial execution and milestone delivery; failure to meet milestones would keep downside risk elevated. MarketBeat NRXP consensus data

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.